Antiglaucoma medications: A review of safety and tolerability issues related to their use

Joel S. Schuman

Research output: Contribution to journalArticlepeer-review


Background: Much experience has been gained with the use of older classes of antiglaucoma agents-topical beta-adrenergic-receptor antagonists, nonselective adrenergic-receptor agonists, oral carbonic anhydrase inhibitors, and cholinergic agents. In the past decade, new drugs and classes of drugs used to treat glaucoma have become available, including topical carbonic anhydrase inhibitors, prostaglandin analogues, and alpha2- adrenergic-receptor agonists. Extensive community-based use of antiglaucoma medications has led to an increased understanding of the acute and long-term safety and tolerability issues associated with their use. Objective: This paper reviews the side effects associated with the various classes of topical antiglaucoma drugs, with a particular focus on long-term safety issues.

Original languageEnglish (US)
Pages (from-to)167-208
Number of pages42
JournalClinical Therapeutics
Issue number2
StatePublished - 2000


  • Adverse effects
  • Beta-adrenergic-receptor antagonists
  • Carbonic anhydrase inhibitors
  • Cholinergic agents
  • Glaucoma
  • Prostaglandin analogues

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Antiglaucoma medications: A review of safety and tolerability issues related to their use'. Together they form a unique fingerprint.

Cite this